S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:ALIM

Alimera Sciences (ALIM) Stock Price, News & Analysis

$3.90
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$3.76
$4.01
50-Day Range
$3.25
$4.21
52-Week Range
$1.56
$4.38
Volume
57,605 shs
Average Volume
82,787 shs
Market Capitalization
$204.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.67

Alimera Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
96.6% Upside
$7.67 Price Target
Short Interest
Healthy
0.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.60mentions of Alimera Sciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.39 out of 5 stars

Medical Sector

338th out of 938 stocks

Pharmaceutical Preparations Industry

148th out of 423 stocks

ALIM stock logo

About Alimera Sciences Stock (NASDAQ:ALIM)

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

ALIM Stock Price History

ALIM Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Q4 2023 Alimera Sciences Inc Earnings Call
A Preview Of Alimera Sciences's Earnings
Alimera Sciences Names Elliot Maltz To Succeed Russell Skibsted As CFO
See More Headlines
Receive ALIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/29/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALIM
Employees
150
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$7.67
High Stock Price Target
$10.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+96.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-20,130,000.00
Pretax Margin
-24.83%

Debt

Sales & Book Value

Annual Sales
$80.75 million
Book Value
$0.88 per share

Miscellaneous

Free Float
35,915,000
Market Cap
$204.17 million
Optionable
Optionable
Beta
1.16

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mr. Richard S. Eiswirth Jr.Mr. Richard S. Eiswirth Jr. (Age 56)
    CEO & Director
    Comp: $597.87k
  • Mr. David R. Holland (Age 60)
    Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets
    Comp: $413.5k
  • Dr. Philip Ashman Ph.D. (Age 59)
    President of International Operations
    Comp: $389.86k
  • Mr. Todd Michael Wood (Age 54)
    President of U.S. Operations
  • Mr. Elliot Maltz CPA (Age 39)
    CFO & Treasurer
  • Mr. Jason Werner
    Chief Operating Officer
  • Christopher S. Visick
    VP, General Counsel & Secretary
  • Dr. David Dyer M.D.
    Chief Retina Specialist

ALIM Stock Analysis - Frequently Asked Questions

Should I buy or sell Alimera Sciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ALIM shares.
View ALIM analyst ratings
or view top-rated stocks.

What is Alimera Sciences' stock price target for 2024?

3 equities research analysts have issued twelve-month price targets for Alimera Sciences' shares. Their ALIM share price targets range from $5.00 to $10.00. On average, they expect the company's stock price to reach $7.67 in the next year. This suggests a possible upside of 96.6% from the stock's current price.
View analysts price targets for ALIM
or view top-rated stocks among Wall Street analysts.

How have ALIM shares performed in 2024?

Alimera Sciences' stock was trading at $4.32 at the beginning of the year. Since then, ALIM shares have decreased by 9.7% and is now trading at $3.90.
View the best growth stocks for 2024 here
.

Are investors shorting Alimera Sciences?

Alimera Sciences saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 85,800 shares, a decline of 27.7% from the February 29th total of 118,600 shares. Based on an average trading volume of 82,500 shares, the short-interest ratio is presently 1.0 days.
View Alimera Sciences' Short Interest
.

When is Alimera Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ALIM earnings forecast
.

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) issued its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by $0.09. The biopharmaceutical company had revenue of $26.31 million for the quarter, compared to the consensus estimate of $25.10 million. Alimera Sciences had a negative trailing twelve-month return on equity of 130.90% and a negative net margin of 24.93%. During the same period last year, the company posted ($0.54) EPS.

When did Alimera Sciences' stock split?

Alimera Sciences's stock reverse split on the morning of Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What guidance has Alimera Sciences issued on next quarter's earnings?

Alimera Sciences updated its FY 2024 earnings guidance on Thursday, March, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $105.0 million-, compared to the consensus revenue estimate of $103.7 million.

What is Rick Eiswirth's approval rating as Alimera Sciences' CEO?

2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB).

Who are Alimera Sciences' major shareholders?

Alimera Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (7.63%), AIGH Capital Management LLC (4.25%), Vanguard Group Inc. (1.24%), Vanguard Group Inc. (1.24%), Worth Venture Partners LLC (1.06%) and Balyasny Asset Management L.P. (0.08%). Insiders that own company stock include Adam Morgan, Alto Investors Lp Palo, Caligan Partners Lp, James R Largent, John Philip Jones, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan.
View institutional ownership trends
.

How do I buy shares of Alimera Sciences?

Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALIM) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners